Alex Hard­ing to chase in­dus­try dreams at CRISPR Ther­a­peu­tics; Scoop: Bio­gen’s head of busi­ness de­vel­op­ment splits for Kite

While Alex Hard­ing is a prac­tic­ing physi­cian, he’s long en­vi­sioned a ca­reer on the busi­ness side of drug de­vel­op­ment. Next year, he’s seiz­ing an op­por­tu­ni­ty to fur­ther those goals at CRISPR Ther­a­peu­tics.

The Swiss-Amer­i­can com­pa­ny an­nounced on Mon­day that Hard­ing — one of End­points News’ 20 un­der 40 hon­orees in 2020 — is join­ing on Jan. 5 as SVP and head of busi­ness de­vel­op­ment. CEO Samarth Kulka­rni said in a news re­lease that the ap­point­ment will be “crit­i­cal in dri­ving the next phase of growth for CRISPR.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER